StoryRegulatory
FDA extends Nerivio to acute migraine treatment in adolescents aged 12 and older
Nerivio's indication was expanded to episodic or chronic migraine in people 12 and older, based on a study published in Headache. The device activates conditioned pain modulation from the upper arm during a 45-minute treatment.
- 71% of adolescents had pain relief at two hours; 35% were pain-free
- Relief held for 24 hours in 90% of cases
- No device-related serious adverse events